NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.01. The company earned $1.45 million during the quarter, compared to analyst estimates of $3.56 million. View Kala Pharmaceuticals' Earnings History.

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Kala Pharmaceuticals.

4 equities research analysts have issued 1 year price objectives for Kala Pharmaceuticals' shares. Their forecasts range from $9.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $21.25 in the next twelve months. This suggests a possible upside of 431.3% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Media coverage about KALA stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View News Stories for Kala Pharmaceuticals.

Kala Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,940,000 shares, an increase of 6.8% from the October 31st total of 3,690,000 shares. Based on an average trading volume of 292,500 shares, the days-to-cover ratio is currently 13.5 days. Approximately 15.2% of the shares of the company are sold short. View Kala Pharmaceuticals' Current Options Chain.

Some companies that are related to Kala Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Aprea Therapeutics (APRE), Intra-Cellular Therapies (ITCI), Provention Bio (PRVB), Kadmon (KDMN), Magenta Therapeutics (MGTA), Viking Therapeutics (VKTX), Prothena (PRTA), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Clovis Oncology (CLVS), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), Morphic (MORF) and Dynavax Technologies (DVAX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Paratek Pharmaceuticals (PRTK), REDHILL BIOPHAR/S (RDHL), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Dynavax Technologies (DVAX).

(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.62%), State Street Corp (0.93%), Point72 Asset Management L.P. (0.90%), Boston Partners (0.36%), Wedbush Securities Inc. (0.26%) and Barclays PLC (0.04%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Kala Pharmaceuticals.

KALA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., State Street Corp, Wedbush Securities Inc. and Boston Partners. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $4.00.

Kala Pharmaceuticals has a market capitalization of $138.16 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]